Periphagen
Manufacturing · Pennsylvania, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
2403 Sidney St Ste 255, Pittsburgh, Penn...Phone Number
(412) 488-0345Website
www.periphagen.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Periphagen
Periphagen is a biopharmaceutical company specializing in peripheral nerve gene therapy, particularly for challenging conditions like neuropathy and chronic pain. They utilize herpes simplex virus type I (HSV-1) as a gene therapy vector, focusing on neurologic diseases while also applying their technology to other medical indications. With over 25 years of experience, they have developed a unique platform called Neuronal Therapeutics (NET) for targeted gene expression in sensory neurons, minimizing systemic side effects. Additionally, Periphagen provides HSV-1 manufacturing services and has supported multiple human clinical trials.Explore more
Periphagen Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Periphagen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Periphagen
Check out if Periphagen is spiking on competitors!
Funding: Get notified immidiatlly once Periphagen has new funding data
Check if Periphagen has recently received funding, and reach out quickly before it becomes old news!
Click to see if Periphagen had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Periphagen, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Periphagen launches new products
Earning: See what the market has to say on Periphagen recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Periphagen
Compare insights from companies similar to Periphagen, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Periphagen is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Periphagen is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Periphagen.
Periphagen financials insights
Gather financial insights about Periphagen, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Private Equity
$6.5M
Periphagen Tech Stack
A closer look at the technologies used by Periphagen
Periphagen News & Media
New Immunological Results That Support Intralymphatic Treatment With Diamyd® to be Presented at the Immunology of Diabetes Society Congress
STOCKHOLM, Oct. 23, 2018 /PRNewswire/ -- New results of intralymphatic treatment with the diabetes vaccine Diamyd® indicate the induction of a long-term immune response that supports the positive clinical results shown in the DIAGNODE-1 trial. The results are presented this week at the...The GABA/Diamyd® trial in the US now fully recruited
The placebo-controlled trial evaluating GABA in combination with Diamyd®, conducted at the University of Alabama at Birmingham in the U.S, is now fully recruited and has included 101 patients. Of these, 56 patients have already completed the entire trial. No serious side effects have been reported. "The trial in Alabama is important in our commitment to GABA-based drugs in diabetes," says Ulf Hannelius, CEO of Diamyd Medical. “It gives us vital insights both regarding GABA:sDiamyd Medical’s Remygen™ for regeneration of insulin-producing cells approved for clinical trials
The Swedish Medical Products Agency has approved the initiation of the clinical Phase I/II trial ReGenerate-1, with Diamyd Medical's patent-pending study drug Remygen™. In addition to evaluating the safety of the study drug, the trial will investigate Remygen's ability to regenerate insulin-producing beta cells in patients with diabetes who have little or no endogenous insulin production. "The positive decision by the MPA is very pleasing and a significant milestone for us as a company asUpdate regarding the manufacturing of Diamyd® drug substance
Diamyd Medical and the Company’s manufacturer of recombinant GAD, the active component of the diabetes vaccine Diamyd®, are working on an updated plan for the new batches of GAD that Diamyd Medical ordered last year for use in late clinical trials and possible early market launch. Manufacturing of the new batches will according to the updated plan be finalized within a time frame that coincides with results from the DIAGNODE-2 trial, which also optimizes the
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Periphagen
Sign Up For FreeTo access detailed company insights
Periphagen is a biopharmaceutical company specializing in peripheral nerve gene therapy, particularly for challenging conditions like neuropathy and chronic pain. They utilize herpes simplex virus type I (HSV-1) as a gene therapy vector, focusing on neurologic diseases while also applying their technology to other medical indications. With over 25... Read More
